4 September 2026 in Formosan Journal of Surgery
Background: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic condition causing persistent bladder-related pain, pressure, or discomfort, significantly impairing quality of life. Cystectomy is a last-resort treatment for severe, refractory cases, but data on outcomes, particularly from specific regions, remain limited. Materials and Methods: This retrospective cohort study analyzed 16 Azerbaijani IC/BPS patients who underwent supratrigonal or total cystectomy between 2014 and 2024. Clinical, radiological, and surgical data were collected, with symptom severity assessed preoperatively and three months postoperatively using the interstitial cystitis symptom index (ICSI), interstitial cystitis problem index (ICPI), and visual analog scale (VAS) for pain. Results: The median age was 57 years, with 75% female. Median symptom duration was 8 years (range: 3-12), anesthetic bladder capacity was 75 mL (range: 40-140), and all patients had Hunner lesions. Surgical interventions included supratrigonal cystectomy with ileal augmentation (12.5%) and simple cystectomy with Bricker ileal conduit diversion (87.5%). Median ICSI scores reduced from 17 (range: 15–19) to 6 (range: 4–8), ICPI from 13 (range: 12–16) to 5 (range: 4–9), and VAS pain scores from 9 (range: 8–10) to 4 (range: 3–5) at the third postoperative month (all p < 0.001). No perioperative complications or in-hospital mortalities occurred, with a median hospital stay of 7 days (range: 6-11). Conclusions: Cystectomy provided substantial symptomatic relief and improved quality-of-life indices in patients with severe, refractory IC/BPS. These findings underscore its role as an effective but complex treatment option for carefully selected patients.
17 November 2024 in Urology Reports (St. - Petersburg)
BACKGROUND: Kidney transplantation is a recognized method of treating patients with end–stage kidney disease. However, the risk of graft loss is not excluded. In Azerbaijan, kidney transplantation is mainly performed from living donors; nevertheless, there is little data on the panel-reactive antibodies (PRA) and its use in the transplantation program. AIM: To evaluate the prevalence of positive panel-reactive antibodies (PRA) and short-term outcomes of living donor kidney transplantation. MATERIALS AND METHODS: Within 6 months after kidney transplantation, 113 recipients were followed up. All patients underwent their first transplantation. Complement-dependent cytotoxicity cross-matching, HLA typing, and flow cytometry cross-matching were carried out. Flow cytometric analysis was applied to detect PRA. The positive response percentage is presented by the percentage of events shifted to the right of the cutoff point. Data were analyzed using SPSS 16.0 statistical software. RESULTS: Among the examined patients, men predominated. In PRA-positive patients (n = 20), the dialysis duration was on average 22.3% longer than in PRA-negative patients (n = 93). 35.0% of PRA-positive patients had class I PRA, 30.0% of patients had class II PRA, and 35.0% had class I + II PRA. In 40.0% of cases, positive PRA had high sensitization 50% (predominantly class II), and the remaining 60.0% had PRA from 10% to 50%. Sensitizing factors were more common in the PRA-positive group (p 0.05). After 6 months of folow-up, the mean creatinine level was 183.4 ± 68.84 nmol/l in the PRA-positive group and 198.15 ± 108.23 nmol/l in the PRA-negative group (p = 0.91). The overall emptying rate was 4.4% (n = 5), with all 5 cases being in the PRA-negative group. No deaths were observed during the follow-up period. CONCLUSIONS: PRA positive patients usually have some sensitizing event such as pregnancy or blood transfusion. The transfusion itself was not a significant factor of sensitization in this study. Patients with high PRA levels require more thorough examination.